Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

[1] Barreca A(2011)Anaplastic lymphoma kinase in human cancer J Mol Endocrinol 47 R11-23

[2] Lasorsa E(2007)Identification of the transforming Eml4-Alk fusion gene in non-small-cell lung cancer Nature 448 561-566

[3] Riera L(2009)Clinical features and outcome of patients with non-small-cell lung cancer who harbor Eml4-Alk J Clin Oncol 27 4247-4253

[4] Machiorlatti R(2014)The Alk inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov 4 662-673

[5] Piva R(2017)First-line ceritinib versus platinum-based chemotherapy in advanced Alk-rearranged non-small-cell lung cancer (Ascend-4): a randomised, open-label, phase 3 study Lancet (London, England) 389 917-929

[6] Ponzoni M(2017)Ceritinib versus chemotherapy in patients with Alk-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (Ascend-5): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 18 874-886

[7] Kwee I(2009)Pharmacokinetic assessment of a five-probe cocktail For Cyps 1a2, 2c9, 2c19, 2d6 and 3a Br J Clin Pharmacol 68 928-935

[8] Bertoni F(2003)Combined phenotypic assessment of cytochrome P450 1a2, 2c9, 2c19, 2d6, and 3a, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 Cocktail" Clin Pharmacol Ther 74 437-447

[9] Pp P(2014)Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies Anal Bioanal Chem 406 7389-7396

[10] Sa P(2014)Ceritinib in Alk-rearranged non-small-cell lung cancer N Engl J Med 370 1189-1197

[1] Barreca A(2011)Anaplastic lymphoma kinase in human cancer J Mol Endocrinol 47 R11-23

[2] Lasorsa E(2007)Identification of the transforming Eml4-Alk fusion gene in non-small-cell lung cancer Nature 448 561-566

[3] Riera L(2009)Clinical features and outcome of patients with non-small-cell lung cancer who harbor Eml4-Alk J Clin Oncol 27 4247-4253

[4] Machiorlatti R(2014)The Alk inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov 4 662-673

[5] Piva R(2017)First-line ceritinib versus platinum-based chemotherapy in advanced Alk-rearranged non-small-cell lung cancer (Ascend-4): a randomised, open-label, phase 3 study Lancet (London, England) 389 917-929

[6] Ponzoni M(2017)Ceritinib versus chemotherapy in patients with Alk-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (Ascend-5): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 18 874-886

[7] Kwee I(2009)Pharmacokinetic assessment of a five-probe cocktail For Cyps 1a2, 2c9, 2c19, 2d6 and 3a Br J Clin Pharmacol 68 928-935

[8] Bertoni F(2003)Combined phenotypic assessment of cytochrome P450 1a2, 2c9, 2c19, 2d6, and 3a, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 Cocktail" Clin Pharmacol Ther 74 437-447

[9] Pp P(2014)Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies Anal Bioanal Chem 406 7389-7396

[10] Sa P(2014)Ceritinib in Alk-rearranged non-small-cell lung cancer N Engl J Med 370 1189-1197